Q-omics provides the consensus-scored IGFBP5 profile across patient tissues and cancer cell-line models. IGFBP5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IGFBP5 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, IGFBP5 protein abundance shows 26,510 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, and GBM as cancer lineages where IGFBP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFBP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFBP5 survival associations across molecular data types. IGFBP5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFBP5 RNA expression–survival associations across cancer types. High IGFBP5 expression shows unfavorable associations in KIRP, LGG, BLCA and UCEC, but favorable associations in UCS and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IGFBP5 RNA expression.
This table summarizes IGFBP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGFBP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFBP5 shows lower tumor expression in KIRP, KIRC, KICH, UCEC and BLCA and higher tumor expression in LUSC. The KIRP box plot shows higher IGFBP5 RNA expression in normal versus tumor tissue (log2 FC = −4.200, t-test p < 0.001).
This table shows molecular features associated with IGFBP5 in patient tissues and cancer cell lines. In patient samples, IGFBP5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFBP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
